Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 The workflow of CAR development from a hybridoma

Published by憬证 郭 Modified over 4 years ago

Similar presentations

Presentation on theme: "Figure 1 The workflow of CAR development from a hybridoma"— Presentation transcript:

1 Figure 1 The workflow of CAR development from a hybridoma
Figure 1 The workflow of CAR development from a hybridoma. (A) The visual depiction of a second-generation CAR design. ... Figure 1 The workflow of CAR development from a hybridoma. (A) The visual depiction of a second-generation CAR design. (B) A simplified roadmap of CAR development and assessment with the focus of the article indicated by the green part of the diagram. (C) Validation of target antigen expression in MAVER-1 (Igλ+, dark gray) and BL-41 (Igκ+, light gray) cell lines with the indicates antibodies. The upper panel was stained with commercial antibodies, and lower was done using the hybridoma supernatants in duplicates at the indicated dilutions. Representative data of two independent experiments are shown. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of Antibody Therapeutics.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Antibody Ther, Volume 2, Issue 2, 31 May 2019, Pages 56–63, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Figure 2 Investigating the hybridoma by 5′-RACE
Figure 2 Investigating the hybridoma by 5′-RACE. (A) The depiction of 5′-RACE step by step protocol. (B) List of ... Figure 2 Investigating the hybridoma by 5′-RACE. (A) The depiction of 5′-RACE step by step protocol. (B) List of primers used in this study and references to already published ones. (C) Acquired gel pictures throughout the 5′-RACE protocol, each kappa and lambda hybridomas were divided into two and the protocol was followed in two replicates (e.g. named as K#1 and K#2). The top picture shows the result of the cDNA synthesis, the middle pictures the first PCR results of dC tailed samples and the bottom pictures the result of the second PCR performed with the first PCR products. The ladder information corresponding to 500 and 400 bp bands were specified as well as the primer dimer with an asterisk on each gel image. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of Antibody Therapeutics.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Antibody Ther, Volume 2, Issue 2, 31 May 2019, Pages 56–63, The content of this slide may be subject to copyright: please see the slide notes for details.

3 Figure 3 The discovery of a scFv sequence and the assembly of the CAR
Figure 3 The discovery of a scFv sequence and the assembly of the CAR. (A) A simplified depiction of the acquisition ... Figure 3 The discovery of a scFv sequence and the assembly of the CAR. (A) A simplified depiction of the acquisition of the heavy and light chain’s sequences through IMGTV database and a general scFv structure. (B) A general description of a second-generation CAR design with the protein sequences of each domains. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of Antibody Therapeutics.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Antibody Ther, Volume 2, Issue 2, 31 May 2019, Pages 56–63, The content of this slide may be subject to copyright: please see the slide notes for details.

4 Figure 4 In vitro validation of CAR constructs
Figure 4 In vitro validation of CAR constructs. (A) Jurkat cells were retrovirally transduced with either IGK (blue) ... Figure 4 In vitro validation of CAR constructs. (A) Jurkat cells were retrovirally transduced with either IGK (blue) or IGL CAR (red). The expression was assessed by flow cytometry detection of anti-Fab antibody. Non-transduced Jurkat cells (gray) were used as baseline control, representative of N > 2. (B) Activated primary T-cells were retrovirally transduced with either IGK (blue) or IGL CAR (red). The expression was assessed by flow cytometry, and mock transduced T cells (gray) were used as a baseline control, representative of N = 2. (C) CAR expressing T cells (IGK, blue; IGL CAR, red; and mock, black) specificity to their respective targets in functional assay. Inset: staining of the target cells with specific antibodies, MAVER-1 (Igλ+, black), BL-41 (Igκ+, light gray) and as a negative control Jurkat (Ig-, white). Cytokine secretion (TNF-α) was analyzed by flow cytometry and plotted. Data represent mean ± SD of triplicates, Student t-test where <sup>**</sup>P < 0.01, <sup>****</sup>P < 0.0001, N = 2. (D) Bioluminescence-based killing assay of CAR expressing T cells (IGK, blue; IGL CAR, red; and mock, black) against the same target cells as in (C) and plotted as percentage of lysis over time. Data represent mean ± SD of quadruplicates, Student t-test where <sup>***</sup>P < 0.001, <sup>****</sup>P < 0.0001, N = 2. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of Antibody Therapeutics.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Antibody Ther, Volume 2, Issue 2, 31 May 2019, Pages 56–63, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1 The workflow of CAR development from a hybridoma"

Similar presentations

Figure 5 ISOX and vorinostat partially restore splicing pattern in DM1 patient-derived fibroblasts. (A) ISOX and vorinostat partially rescue mis-splicing.

Figure 5 ISOX and vorinostat partially restore splicing pattern in DM1 patient-derived fibroblasts. (A) ISOX and vorinostat partially rescue mis-splicing.
Fig. 1 Nodes in a conceptual knowledge graph

Fig. 1 Nodes in a conceptual knowledge graph
Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.

Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.
Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:

Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:
Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.

Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.
Figure 1. Circular taxonomy tree based on the species that were sequenced in our study. Unless provided in the caption above, the following copyright applies.

Figure 1. Circular taxonomy tree based on the species that were sequenced in our study. Unless provided in the caption above, the following copyright applies.
ADAb: anti-drug antibody.

ADAb: anti-drug antibody.
Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.

Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.
FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.

FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.
FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels

FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels
Figure 1. BRCA1-associated R-Loop accumulation at a non-coding region upstream of ESR1 locus. (A) Alignment of DRIP-seq ... Figure 1. BRCA1-associated.

Figure 1. BRCA1-associated R-Loop accumulation at a non-coding region upstream of ESR1 locus. (A) Alignment of DRIP-seq ... Figure 1. BRCA1-associated.
FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:

FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:
FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.

FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.
FIGURE 1 Flow chart of patient enrollment and exclusion

FIGURE 1 Flow chart of patient enrollment and exclusion
Figure 1. Ratios of observed to expected numbers of exon boundaries aligning to boundaries of domain and disorder ... Figure 1. Ratios of observed to expected.

Figure 1. Ratios of observed to expected numbers of exon boundaries aligning to boundaries of domain and disorder ... Figure 1. Ratios of observed to expected.
Figure 1. autoMLST workflow depicting placement and de novo mode

Figure 1. autoMLST workflow depicting placement and de novo mode
Fig. 1 Kaplan-Meier plot of cumulative incidence of cancer onset following dermatomyositis diagnosis stratified ... Anti-TIF1-Ab: anti-transcriptional.

Fig. 1 Kaplan-Meier plot of cumulative incidence of cancer onset following dermatomyositis diagnosis stratified ... Anti-TIF1-Ab: anti-transcriptional.
Figure 1 KCTD16 antibodies are associated with an underlying tumour

Figure 1 KCTD16 antibodies are associated with an underlying tumour
Figure 1 Flortaucipir PET MUBADA/PERSI SUVr at baseline, 9 and 18 months for individual subjects. Each subject is ... Figure 1 Flortaucipir PET MUBADA/PERSI.

Figure 1 Flortaucipir PET MUBADA/PERSI SUVr at baseline, 9 and 18 months for individual subjects. Each subject is ... Figure 1 Flortaucipir PET MUBADA/PERSI.
Fig. 1 Mean change from baseline in ANC ± s. e

Fig. 1 Mean change from baseline in ANC ± s. e

Similar presentations

Ads by Google